Dr. Clarke is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Dumc
Box 3951
Durham, NC 27710Phone+1 317-670-7833
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 2011 - 2014- Duke University HospitalResidency, Internal Medicine, 2008 - 2011
Indiana University School of MedicineClass of 2008
Certifications & Licensure
NC State Medical License 2008 - 2025- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902) Start of enrollment: 2020 Jun 09
Publications & Presentations
PubMed
- 1 citationsT-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study.Justin F Gainor, Manish R Patel, Jeffrey S Weber, Martin Gutierrez, Julie E Bauman
Cancer Discovery. 2024-11-01 - Neighborhood-level socioeconomic disparities in Radon testing in North Carolina from 2010 to 2020.Zhenchun Yang, Lauren Prox, Clare Meernik, Yadurshini Raveendran, Phillip Gibson
Journal of Environmental Radioactivity. 2024-07-01 - Differences in microenvironment of lung cancer and pleural effusions by single-cell RNA sequencing.Kamran Mahmood, Huimin Wang, Zhicheng Ji, Coral X Giovacchini, Momen M Wahidi
Lung Cancer. 2024-07-01
Lectures
- Real-world (rw) clinical outcomes for advanced/metastatic non-small cell lung cancer (aNSCLC) patients (pts) treated with second line (2L) ramucirumab plus docetaxel (...2019 ASCO Annual Meeting - 6/1/2019
- Real-world tumor response (rwTR) to ramucirumab plus docetaxel (R+D) post platinum-based (Pt) and immune checkpoint inhibitor (ICI) therapy in advanced non-small cell ...2019 ASCO Annual Meeting - 6/1/2019
- Veliparib in combination with nivolumab and platinum doublet chemotherapy (CT) in metastatic/advanced NSCLC.2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Press Mentions
Poziotinib Shows Promise in Hard-to-Treat NSCLC Exon 20 MutationsNovember 7th, 2019
Spectrum Announces Expansion of the Poziotinib Clinical ProgramJuly 22nd, 2019- OncLive® Presents State of the Science Summit™ on Non-Small Cell Lung CancerMay 8th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
